Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 6:12:721975.
doi: 10.3389/fimmu.2021.721975. eCollection 2021.

HBV-Specific CD8+ T-Cell Tolerance in the Liver

Affiliations
Review

HBV-Specific CD8+ T-Cell Tolerance in the Liver

Ian Baudi et al. Front Immunol. .

Abstract

Hepatitis B virus (HBV) remains a leading cause of liver-related morbidity and mortality through chronic hepatitis that may progress to liver cirrhosis and cancer. The central role played by HBV-specific CD8+ T cells in the clearance of acute HBV infection, and HBV-related liver injury is now well established. Vigorous, multifunctional CD8+ T cell responses are usually induced in most adult-onset HBV infections, while chronic hepatitis B (CHB) is characterized by quantitatively and qualitatively weak HBV-specific CD8+ T cell responses. The molecular basis of this dichotomy is poorly understood. Genomic analysis of dysfunctional HBV-specific CD8+ T cells in CHB patients and various mouse models suggest that multifaceted mechanisms including negative signaling and metabolic abnormalities cooperatively establish CD8+ T cell dysfunction. Immunoregulatory cell populations in the liver, including liver resident dendritic cells (DCs), hepatic stellate cells (HSCs), myeloid-derived suppressor cells (MDSCs), may contribute to intrahepatic CD8+ T cell dysfunction through the production of soluble mediators, such as arginase, indoleamine 2,3-dioxygenase (IDO) and suppressive cytokines and the expression of co-inhibitory molecules. A series of recent studies with mouse models of HBV infection suggest that genetic and epigenetic changes in dysfunctional CD8+ T cells are the manifestation of prolonged antigenic stimulation, as well as the absence of co-stimulatory or cytokine signaling. These new findings may provide potential new targets for immunotherapy aiming at invigorating HBV-specific CD8+ T cells, which hopefully cures CHB.

Keywords: T cell exhaustion; co-inhibitory signaling; hepatitis B virus; interferon signaling; intrahepatic antigen recognition; liver tolerance; metabolic regulation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Potential mechanisms of HBV-specific CD8+ T cell dysfunction. Top panel: Illustration of how persistent antigen recognition, predominantly by HBV infected hepatocytes, results in dysfunctional HBV-specific CD8+ T cells that fail to clear infection. Bottom panel: Illustration of how systemic and hepatic antigen recognition may cooperatively trigger robust HBV-specific CD8+ T cell responses that result in viral clearance.

References

    1. Thomas DL. Global Elimination of Chronic Hepatitis. N Engl J Med (2019) 380:2041–50. 10.1056/nejmra1810477 - DOI - PubMed
    1. Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B Cure: From Discovery to Regulatory Approval. Hepatology (2017) 66:1296–313. 10.1002/hep.29323 - DOI - PMC - PubMed
    1. World Health Organization (WHO) . Global Hepatitis Report (2017). Available at: https://www.who.int/publications/i/item/global-hepatitis-report-2017.
    1. Arbuthnot P, Kew M. Hepatitis B Virus and Hepatocellular Carcinoma. Int J Exp Pathol (2001) 82:77–100. 10.1186/1750-9378-7-2 - DOI - PMC - PubMed
    1. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, et al. . CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis During Acute Hepatitis B Virus Infection. J Virol (2003) 77:68–76. 10.1128/jvi.77.1.68-76.2003 - DOI - PMC - PubMed

Publication types

MeSH terms